Market Intelligence, Clinical Progress, and High-Purity Reagents for CLN2 Disease and Lysosomal Storage Disorder Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TPP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPP1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View TPP1 Products |
| Gene Delivery | TPP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for target expression validation. |
View TPP1 Products |
| Benchmark Ab | Anti-TPP1 (Sequence of Cerliponase alfa) Recombinant positive control for assay validation. |
View TPP1 Products |
| Validator | TPP1 siRNA Set For knockdown verification in functional assays. |
View TPP1 Products |
| Related Target A | IGF2R Cation-independent mannose-6-phosphate receptor (CI-MPR), critical for TPP1 lysosomal targeting. |
View IGF2R Products |
| Related Target B | PPT1 Palmitoyl-protein thioesterase 1, key target for synergistic Batten disease (CLN1) screening. |
View PPT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| M6PR-Mediated Cellular Uptake | HEK293 expression system preserves native high-mannose and phosphomannose (M6P) glycans. |
| Pro-enzyme Auto-activation | Sequence-verified pro-TPP1 constructs optimized for low-pH in vitro activation assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TPP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TPP1 therapeutics is intensifying, with major players shifting focus from traditional enzyme replacement therapies (ERT) to long-acting gene therapies and blood-brain barrier (BBB)-crossing fusion proteins. As first-generation therapies reach the clinic, the next wave of R&D is targeting improved CNS biodistribution and reduced immunogenicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement (ERT) | BioMarin Pharmaceutical | CLN2 Disease (Batten Disease) | Uptake Assay (Need high-purity, native-glycosylated TPP1) |
| Gene Therapy (AAV) | REGENXBIO, LYSOGENE | Late Infantile CLN2 | Expression Validation (Need specific anti-TPP1 Abs & Lentivirus) |
| BBB-Crossing Fusion | Academic / Biotech Startups | Neurodegenerative LSDs | Receptor Binding Assay (Need dual-active TPP1-transferrin fusions) |